3 research outputs found
Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD)
Peripheral arterial disease (PAD) is associated with a high risk of cardiovascular events and death
and is postulated to be a critical socioeconomic cost in the future. Extracellular vesicles (EVs) have
emerged as potential candidates for new biomarker discovery related to their protein and nucleic
acid cargo. In search of new prognostic and therapeutic targets in PAD, we determined the
prothrombotic activity, the cellular origin and the transcriptomic profile of circulating EVs. This
prospective study included control and PAD patients. Coagulation time (Procoag-PPL kit), EVs
cellular origin and phosphatidylserine exposure were determined by flow cytometry in plateletfree plasma (n = 45 PAD). Transcriptomic profiles of medium/large EVs were generated using the
MARS-Seq RNA-Seq protocol (n = 12/group). The serum concentration of the differentially
expressed gene S100A9, in serum calprotectin (S100A8/A9), was validated by ELISA in control
(n = 100) and PAD patients (n = 317). S100A9 was also determined in EVs and tissues of human
atherosclerotic plaques (n = 3). Circulating EVs of PAD patients were mainly of platelet origin,
predominantly Annexin V positive and were associated with the procoagulant activity of plateletfree plasma. Transcriptomic analysis of EVs identified 15 differentially expressed genes. Among
them, serum calprotectin was elevated in PAD patients (p < 0.05) and associated with increased
amputation risk before and after covariate adjustment (mean follow-up 3.6 years, p < 0.01). The
combination of calprotectin with hs-CRP in the multivariate analysis further improved risk
stratification (p < 0.01). Furthermore, S100A9 was also expressed in femoral plaque derived EVs
and tissues. In summary, we found that PAD patients release EVs, mainly of platelet origin, highly
positive for AnnexinV and rich in transcripts related to platelet biology and immune responses.
Amputation risk prediction improved with calprotectin and was significantly higher when combined with hs-CRP. Our results suggest that EVs can be a promising component of liquid biopsy
to identify the molecular signature of PAD patients
Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD)
Peripheral arterial disease (PAD) is associated with a high risk of cardiovascular events and death
and is postulated to be a critical socioeconomic cost in the future. Extracellular vesicles (EVs) have
emerged as potential candidates for new biomarker discovery related to their protein and nucleic
acid cargo. In search of new prognostic and therapeutic targets in PAD, we determined the
prothrombotic activity, the cellular origin and the transcriptomic profile of circulating EVs. This
prospective study included control and PAD patients. Coagulation time (Procoag-PPL kit), EVs
cellular origin and phosphatidylserine exposure were determined by flow cytometry in plateletfree plasma (n = 45 PAD). Transcriptomic profiles of medium/large EVs were generated using the
MARS-Seq RNA-Seq protocol (n = 12/group). The serum concentration of the differentially
expressed gene S100A9, in serum calprotectin (S100A8/A9), was validated by ELISA in control
(n = 100) and PAD patients (n = 317). S100A9 was also determined in EVs and tissues of human
atherosclerotic plaques (n = 3). Circulating EVs of PAD patients were mainly of platelet origin,
predominantly Annexin V positive and were associated with the procoagulant activity of plateletfree plasma. Transcriptomic analysis of EVs identified 15 differentially expressed genes. Among
them, serum calprotectin was elevated in PAD patients (p < 0.05) and associated with increased
amputation risk before and after covariate adjustment (mean follow-up 3.6 years, p < 0.01). The
combination of calprotectin with hs-CRP in the multivariate analysis further improved risk
stratification (p < 0.01). Furthermore, S100A9 was also expressed in femoral plaque derived EVs
and tissues. In summary, we found that PAD patients release EVs, mainly of platelet origin, highly
positive for AnnexinV and rich in transcripts related to platelet biology and immune responses.
Amputation risk prediction improved with calprotectin and was significantly higher when combined with hs-CRP. Our results suggest that EVs can be a promising component of liquid biopsy
to identify the molecular signature of PAD patients
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-kappaB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF) combinatorially activated in B lymphocytes following T cell-driven immunization. Fifteen genetically diverse models developed bone marrow (BM) tumors fulfilling MM pathogenesis. Integrative analyses of 500 mice and 1,000 patients revealed a common MAPK-MYC genetic pathway that accelerated time to progression from precursor states across genetically heterogeneous MM. MYC-dependent time to progression conditioned immune evasion mechanisms that remodeled the BM microenvironment differently. Rapid MYC-driven progressors exhibited a high number of activated/exhausted CD8+ T cells with reduced immunosuppressive regulatory T (Treg) cells, while late MYC acquisition in slow progressors was associated with lower CD8+ T cell infiltration and more abundant Treg cells. Single-cell transcriptomics and functional assays defined a high ratio of CD8+ T cells versus Treg cells as a predictor of response to immune checkpoint blockade (ICB). In clinical series, high CD8+ T/Treg cell ratios underlie early progression in untreated smoldering MM, and correlated with early relapse in newly diagnosed patients with MM under Len/Dex therapy. In ICB-refractory MM models, increasing CD8+ T cell cytotoxicity or depleting Treg cells reversed immunotherapy resistance and yielded prolonged MM control. Our experimental models enable the correlation of MM genetic and immunological traits with preclinical therapy responses, which may inform the next-generation immunotherapy trials